Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Désirée Van Der Heijde, Atul Deodhar, James C. Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S. Kanik

Research output: Contribution to journalArticlepeer-review

158 Scopus citations

Fingerprint

Dive into the research topics of 'Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences